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Abstract Vagal nerve stimulation (VNS) started prior to,
or during, ischemia has been shown to reduce infarct size.
Here, we investigated the effect of VNS when started just
prior to, and continued during early, reperfusion on infarct
size and no-reflow and studied the underlying mechanisms.
For this purpose, swine (13 VNS, 10 sham) underwent
45 min mid-LAD occlusion followed by 120 min of
reperfusion. VNS was started 5 min prior to reperfusion
and continued until 15 min of reperfusion. Area at risk,
area of no-reflow (% of infarct area) and infarct size (% of
area at risk), circulating cytokines, and regional myocardial
leukocyte influx were assessed after 120 min of reperfu-
sion. VNS significantly reduced infarct size from
67 ± 2 % in sham to 54 ± 5 % and area of no-reflow from
54 ± 6 % in sham to 32 ± 6 %. These effects were
accompanied by reductions in neutrophil (*40 %) and
macrophage (*60 %) infiltration in the infarct area (all
p\ 0.05), whereas systemic circulating plasma levels of
TNFa and IL6 were not affected. The degree of
cardioprotection could not be explained by the VNS-in-
duced bradycardia or the VNS-induced decrease in the
double product of heart rate and left ventricular systolic
pressure. In the presence of NO-synthase inhibitor LNNA,
VNS no longer attenuated infarct size and area of no-re-
flow, which was paralleled by similarly unaffected regional
leukocyte infiltration. In conclusion, VNS is a promising
novel adjunctive therapy that limits reperfusion injury in a
large animal model of acute myocardial infarction.
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Introduction
The single most effective therapy to limit myocardial
infarct size and improve clinical outcome after acute
myocardial infarction is early coronary reperfusion via
primary percutaneous coronary intervention [41, 43].
However, despite its overall benefits, reperfusion therapy
has been shown to result in additional cardiomyocyte
death, termed lethal reperfusion injury [12, 19, 52], and in
microvascular obstruction, termed no-reflow [38]. No-re-
flow refers to inadequate myocardial reperfusion following
opening of the culprit coronary lesion, despite lack of
angiographic evidence of epicardial vessel obstruction and
may be present in 30–40 % of patients [34]. Since both
infarct size [30] and extent of no-reflow [17, 33, 38] are
independent predictors of clinical outcome, strategies to
limit these two components of reperfusion injury have
significant therapeutic potential.
A novel strategy against ischemia–reperfusion injury
was proposed by Katare et al. [21], who demonstrated that
vagal nerve stimulation (VNS) limited infarct size in rats.
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This initial observation was confirmed in subsequent
studies in rats [8, 25, 48, 54], mice [22] and swine [40]. In
these studies, VNS was started either before [8, 21, 54], at
the very onset of [22, 25, 40], or halfway through [39, 48]
the period of ischemia. In contrast, a recent study reported
that an intermittent VNS protocol failed to attenuate infarct
size when started at the very onset of reperfusion [39]. In
view of the critical importance of the presence of an
intervention during the golden first minute(s) of reperfusion
[42], we hypothesized that continuous VNS started just
prior to reperfusion might be effective against reperfusion
injury. Consequently, the first aim of the present study was
to investigate the effects of continuous VNS starting 5 min
prior to reperfusion [to ensure full VNS during the first
minute(s) of reperfusion] on infarct size in a large animal
model of ST-elevation myocardial infarction (STEMI).
Moreover, since none of the aforementioned studies
assessed the effects of VNS on no-reflow, despite its
prognostic potential in the clinical setting [17, 33, 38], the
second aim of the present study was to investigate the
effects of VNS on no-reflow.
The mechanisms underlying the cardioprotective effects
of VNS against myocardial necrosis are incompletely
understood, but have been proposed to include activation of
muscarinic receptors [40] and blunting of the inflammatory
response [48]. Consequently, the second aim of the present
study was to investigate the potential mechanisms under-
lying the effects of VNS on infarct size and no-reflow, in
particular anti-inflammatory actions, including circulating
inflammatory cytokines and myocardial neutrophil and
macrophage infiltration, and the nitric oxide synthase
(NOS) signaling pathway.
Materials and methods
Studies were performed in 63 Yorkshire 9 Landrace swine
(*55 kg) of either sex, in accordance with the ‘‘Guiding
Principles in the Care and Use of Laboratory Animals’’ as
approved by the Council of the American Physiological
Society, and with approval of the Animal Care Committee
of the Erasmus MC Rotterdam.
Animal preparation
Swine were sedated with ketamine (20 mg/kg, i.m.) and
midazolam (1 mg/kg, i.m.), anesthetized with pentobarbital
(15 mg/kg i.v.), intubated and mechanically ventilated with
O2 and N2 (1:3 v/v), and instrumented as previously
described [26, 44]. Catheters were placed in the external
jugular vein for maintenance of anesthesia (pentobarbital,
10–15 mg/kg/h) and infusion of physiological saline, and
the left femoral artery for measurement of arterial blood
pressure. A Swan–Ganz catheter was inserted into the left
femoral vein and advanced into the pulmonary artery for
body core temperature monitoring. A micromanometer-
tipped catheter (SPC-3705, Millar Instruments, Houston,
USA) was inserted into the right carotid artery and
advanced into the left ventricle (LV) for measurement of
LV pressure and its first derivative (LVdP/dt). Following
sternotomy, an electromagnetic flow probe (P18, Skalar
Medical, Delft, The Netherlands) was placed around the
ascending aorta to measure cardiac output, and a transit-
time flow probe (3SB, Transonic Systems, Ithaca, USA)
was placed around the left anterior descending coronary
artery (LAD) for measurement of coronary blood flow. A
suture was placed around the LAD, just distal to its first
diagonal branch, to enable coronary artery occlusion
(CAO) during the experimental protocol. Regional
myocardial function was measured in the area at risk and
remote myocardium using two pairs of ultrasonic crystals
(P/N SL5-2, Triton Technology Inc., San Diego, USA)
placed in the mid-myocardium [11, 44]. A fluid-filled
catheter was placed in the left atrium through a purse-string
suture into the auricle for measurement of left atrial pres-
sure. For coronary venous blood sampling, a custom fluid-
filled catheter was placed in the anterior coronary vein
draining the perfusion territory of the LAD. Heparin (5000
i.u./h, i.v.) was administered throughout the experiment to
prevent coagulation.
Custom-made, self-coiling cuff electrodes were placed
around both the left and right vagal nerves for VNS. After
completion of instrumentation, the cardiac vagal nerve
reserve (maximal percent reduction in heart rate) was tes-
ted in both vagal nerves (left and right) in 1 min intervals
by increasing voltages (Medtronic 3625 test simulator;
2.0–10.5 V; 10 mA; pulse width 0.3 ms; 25 Hz). The
maximum effect of VNS was reached during stimulation
with 10.5 V. Maximum heart rate reductions during ther-
apy, produced by stimulation of either left (15 ± 2 %) or
right vagal nerve (18 ± 3 %), were not different
(p = 0.41). Maximum heart rate reductions at pre-ischemia
baseline were also comparable between VNS (23 ± 2 %)
and sham (21 ± 3 %) groups (p = 0.69).
Experimental protocols
Cardioprotection by VNS
After 30 min of stabilization, swine were subjected to the
experimental protocol. Systemic and coronary hemody-
namics and regional myocardial function were continu-
ously recorded. Blood samples were obtained from the
aorta and anterior interventricular coronary vein at several
time points for measurement of PO2 (mmHg), PCO2
(mmHg), pH, O2 saturation (%), hemoglobin (Hb, in
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grams per 100 ml) and lactate (lmol/l) (Acid–Base Lab-
oratory model 800, Radiometer, Copenhagen, Denmark).
Body core temperature was monitored and maintained
between 37.0 and 38.0 C throughout the experimental
protocol [13]. Swine were subjected to a 45-min CAO
followed by 120 min of reperfusion. Swine encountering
ventricular fibrillation (VF) were allowed to complete the
protocol if conversion to sinus rhythm was successful
within 2 min after onset of VF. Swine were randomly
assigned to either sham treatment (n = 13) or VNS alone
(n = 17). VNS was started 5 min before the end of CAO
and continued until 15 min into reperfusion. All VNS
animals were initially subjected to stimulation of the left
vagal nerve. In five animals, in which the reduction in
heart rate during the first minute was less than 10 %, right
vagal nerve stimulation was applied during the remainder
of the 20-min stimulation protocol.
Role of NO-synthase
To investigate the role of NO signaling in the protection by
VNS, we performed a second series of experiments in
which we studied three additional groups of swine. Ani-
mals underwent the identical 45-min CAO and 120-min
reperfusion protocol, as outlined above, while receiving (1)
control–sham treatment (n = 11), (2) NO-synthase inhibi-
tion, using Nx-nitro-L-arginine (LNNA, Sigma, Zwijn-
drecht, The Netherlands) 10 mg/kg i.v. 30 min before
CAO [27], and sham treatment (n = 10), or (3) LNNA and
VNS (n = 12).
Infarct size and area of no-reflow
At the end of 120 min of reperfusion, a fluid-filled catheter
was inserted into the coronary artery, distal to the site of
occlusion, to administer 5 ml of a 4 % (w/v) thioflavin-S
(Sigma) solution to determine the area of no-reflow [36,
45]. The coronary artery was re-occluded and the area at
risk was delineated by intra-atrial infusion of 40 ml of
15 % (w/v) Evans Blue [13, 26]. Then, the heart was
excised, the LV was isolated and cut into five transverse
slices of equal thickness, and slices were weighed. After
the area at risk and area of no-reflow (using UV light) of
each slice were demarcated on an acetate sheet, the slices
were incubated in 3 % (w/v) 2,3,5-triphenyltetrazolium
chloride at 37 C for 15 min to stain metabolically active
tissue [13] and delineate infarcted area from non-infarcted
area. The red stained non-infarcted area was also traced
onto the sheet. The area at risk, area of no-reflow, and
infarct area from each of the five transverse slices were
determined and summed. Myocardial infarct size (IS) was
defined as the ratio of the summed infarct areas (IA) and
summed areas at risk (AR): IS = IA/AR 9 100 % [13,
26]. Area of no-reflow (NR) was defined as the ratio of the
summed no-reflow areas (NA) and summed infarct areas:
NR = NA/IA 9 100 % [36].
Systemic inflammation
Plasma isolated from arterial blood taken at baseline, prior
to CAO, and the first hour of reperfusion was analyzed by
ELISA according to the manufacturer’s instructions for
porcine inflammatory markers TNFa and IL6 (R&D Sys-
tems, Abingdon, UK).
Regional inflammation
Infarct area with either reflow or no-reflow and remote non-
area at risk (posterior wall) LV tissue was fixed in 4 %
buffered formaldehyde and embedded in paraffin. To iden-
tify the acute influx of immune cells, sections of 4 lm were
stained for neutrophils (Azurocidin, mouse anti human,
1:100, Abnova, Heidelberg, Germany) following antigen
retrieval (10 min citrate buffer boil (pH 6)) and for macro-
phages (MAC387, mouse anti macrophage, 1:100, Abcam,
Cambridge, United Kingdom). Staining was visualized using
rabbit anti-mouse secondary antibodies (1:100, horseradish
peroxidase label, DAKO, Heverlee, Belgium) with 3,30-di-
aminobenzidine (DAB, DAKO) and H2O2 as chromogen.
Primary antibodies were omitted as a negative control. Three
randomly selected high power fields (90,000 lm2 per field)
per section were morphometrically quantified in a blinded
manner using dedicated software (Clemex Vision PE, ver-
sion 6.0.010A, Clemex Technologies inc, Longueuil,
Canada). Data were expressed as the number of cells/mm2.
Data and statistical analysis
Hemodynamic and LV global and regional function data
were recorded and analyzed, and myocardial oxygen and
lactate consumption, and systolic and post-systolic short-
ening were calculated, as previously described [26, 44].
Inter-group differences in AR/LV, IA/AR and NR/IA
were analyzed using unpaired t test or one-way ANOVA
followed by Student–Newman–Keuls (SNK) post hoc
testing, as appropriate. Hemodynamics and LV function
were analyzed using two-way (time 9 treatment) ANOVA
followed by SNK test. Global and regional inflammation
were also analyzed using two-way (treatment 9 location)
ANOVA followed by SNK test. Values are expressed as
mean ± SEM. p\ 0.05 (two tailed) was considered to be
statistically significant.
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Results
Mortality
In the first series of experiments, 26 out of 30 swine (11
out of 13 sham, 15 out of 17 VNS) encountered VF
during the 45 min of CAO (all prior to VNS or sham).
Seven out of these 26 swine (3 out of 11 sham, 4 out of
15 VNS) could not be successfully converted to sinus
rhythm within 2 min and were therefore excluded from
further study. The numbers of animals that encountered
VF but could be converted to sinus rhythm within 2 min
and completed the experimental protocol were not dif-
ferent (p = 0.76) between sham (8 out of 10 swine;
80 %) and VNS (11 out of 13 VNS; 85 %). Moreover, the
average number of VF episodes before the start of VNS
(1.8 ± 0.4) or sham (1.4 ± 0.4) treatment in these ani-
mals was also similar between groups (p = 0.45).
Importantly, VF did not occur during VNS or the corre-
sponding sham period or after 15 min of reperfusion,
except for one sham animal that encountered VF at 11
and 15 min of reperfusion.
In the second series of experiments, 11 out of 11 (100 %)
control–sham, and 17 out of 22 (77 %) LNNA-treated
swine (p = 0.09) encountered VF during the 45 min of
CAO (all prior to sham or VNS treatment). However, of the
animals that encountered VF, 53 % (9 out of 17) LNNA-
treated swine versus 27 % (3 out of 11) control–sham ani-
mals (p = 0.19) could not be successfully converted to
sinus rhythm within 2 min and hence did not complete the
experimental protocol. Finally, two swine (LNNA ? VNS)
developed progressive pump failure during reperfusion and
could not complete the experimental protocol.
Hemodynamics and global and regional LV function
Coronary artery occlusion of the LAD produced complete
loss of regional systolic segment shortening, accompanied
by an increase in post-systolic shortening in the LAD
perfusion territory, which resulted in decreases in LV
systolic pressure, LVdP/dtP40, stroke volume, cardiac out-
put, and mean aortic pressure (Table 1). Global and
regional LV function remained severely depressed during
the 120-min reperfusion period.
The 18 ± 2 % decrease in heart rate produced by VNS
was associated with a 19 ± 2 % decrease in cardiac output
and a 16 ± 4 and 13 ± 3 % decrease, respectively, in
mean aortic and LV peak systolic pressure at 45 min of
CAO (Table 1). VNS did not alter LVdP/dtP40, LV end-
diastolic pressure, or regional systolic and post-systolic
segment shortening, indicating that VNS did not affect
global or regional LV function. These effects of VNS were
maintained during reperfusion, although heart rate showed
partial escape from VNS during the first 5 min of reper-
fusion, which was likely due to the occurrence of prema-
ture ventricular contractions. After the termination of VNS,
systemic hemodynamics and global and regional LV
function were no longer different between VNS and sham
swine.
Coronary blood flow and myocardial metabolism
During reperfusion, transient increases in coronary blood
flow and coronary vascular conductance were observed,
together with a transient reversal from lactate consumption
to production and a sustained depression of oxygen con-
sumption (Table 2).
There were no significant differences between VNS and
sham swine in the responses of coronary blood flow,
coronary vascular conductance, myocardial consumption,
and extraction of oxygen or lactate during early reperfusion
(Table 2; Supplemental Figure S1).
Infarct size and area of no-reflow
Ligation of the LAD distal to the first diagonal branch
resulted in an average area at risk of 26 ± 1 % of the LV
(Figs. 1, 2) and did not differ between sham (26 ± 1 %)
and VNS (27 ± 1 %; p = 0.60). CAO of 45 min resulted
in an infarct size in sham swine of 67 ± 2 % of the area at
risk and a no-reflow area of 54 ± 6 % of the infarct area.
VNS reduced infarct size to 54 ± 5 %, which was
accompanied by a decrease in no-reflow area to 32 ± 6 %
(both p = 0.03). There were no differences between swine
undergoing left or right VNS, in terms of infarct size (left
52 ± 7 vs. right 58 ± 7 %, p = 0.56) or no-reflow area
(left 32 ± 9 vs. right 32 ± 10 %, p = 1.00).
Systemic and regional inflammation
Systemic TNFa levels did not rise in the early phase after
reperfusion, while IL6 increased significantly compared to
baseline but no differences between treatment groups were
found (Fig. 3).
In control animals, neutrophil and macrophage numbers
were increased in the infarct area as compared to the
remote myocardium, measured after 120 min of reperfu-
sion. VNS attenuated neutrophil as well as macrophage
influx into the infarct area (Figs. 4, 5).
Role of NO-synthase
Infusion of LNNA in 11 swine resulted in an 18 ± 5 %
increase in mean arterial pressure from 91 ± 4 to
108 ± 8 mmHg, which was accompanied by a 9 ± 1 %
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decrease in heart rate from 107 ± 7 to 98 ± 6 bpm, and an
18 ± 2 % decrease in cardiac output from 3.9 ± 0.1 to
3.2 ± 0.1 l/min (all p\ 0.01). LNNA did not affect the
responses to ischemia and reperfusion of systemic hemo-
dynamics and global and regional LV function
(Supplemental Table S1), or coronary hemodynamics and
myocardial metabolism (Supplemental Table S2). Impor-
tantly, LNNA did not modify the hemodynamic, functional
and metabolic responses to VNS (Supplemental Tables S1
and S2).
Table 1 Systemic hemodynamics and global and regional left ventricular function
Baseline Coronary artery occlusion Reperfusion
40 min 45 min 15 min 120 min
Systemic hemodynamics
HR (bpm)
Sham 111 ± 6 117 ± 8 116 ± 8 113 ± 7 109 ± 5
VNS 103 ± 4 107 ± 4 87 ± 4* 89 ± 3* 109 ± 4
MAP (mmHg)
Sham 94 ± 3 82 ± 3* 80 ± 3* 76 ± 4* 73 ± 3*
VNS 91 ± 3 77 ± 5* 65 ± 5* 65 ± 4* 71 ± 3*
CO (l/min)
Sham 4.2 ± 0.3 3.4 ± 0.1* 3.3 ± 0.1* 3.3 ± 0.2* 2.8 ± 0.1*
VNS 3.5 ± 0.1 2.9 ± 0.2* 2.3 ± 0.1* 2.4 ± 0.2* 2.5 ± 0.1*
SV (ml)
Sham 38 ± 2 30 ± 2* 30 ± 2* 30 ± 2* 26 ± 2*
VNS 34 ± 2 27 ± 1* 27 ± 2* 28 ± 2* 23 ± 2*
Global and regional LV function
LVSP (mmHg)
Sham 109 ± 3 95 ± 3* 93 ± 3* 90 ± 3* 85 ± 4*
VNS 106 ± 2 90 ± 5* 78 ± 5* 79 ± 4* 85 ± 3*
LVdP/dtP = 40 (mmHg/s)
Sham 1700 ± 160 1340 ± 80* 1320 ± 60* 1330 ± 80* 1120 ± 60*
VNS 1600 ± 70 1250 ± 80* 1060 ± 70* 1100 ± 80* 1110 ± 50*
LVEDP (mmHg)
Sham 14 ± 1 16 ± 1 15 ± 1 16 ± 1 15 ± 1
VNS 13 ± 1 17 ± 1* 16 ± 1* 18 ± 1* 16 ± 1*
SSLAD (%)
Sham 15.1 ± 1.4 -7.2 ± 1.0* -5.9 ± 0.7* 0.7 ± 0.4* 0.2 ± 0.6*
VNS 21.2 ± 1.2 -8.8 ± 1.3* -7.0 ± 1.2* 2.0 ± 1.2* 0.1 ± 1.3*
SSLCx (%)
Sham 17.2 ± 2.2 12.8 ± 2.0* 12.8 ± 1.9* 13.9 ± 1.3* 10.8 ± 1.1*
VNS 17.2 ± 1.4 17.4 ± 1.2 17.7 ± 1.3 18.1 ± 1.4 15.4 ± 1.2
PSSLAD (%)
Sham 0.9 ± 0.2 10.7 ± 1.3* 9.0 ± 1.1* 2.3 ± 0.4 2.9 ± 0.7
VNS 1.2 ± 0.4 15.0 ± 1.1* 12.5 ± 1.1* 4.3 ± 1.3* 5.0 ± 1.4*
PSSLCx (%)
Sham 0.5 ± 0.2 1.2 ± 0.5 1.1 ± 0.5 0.3 ± 0.1 0.7 ± 0.2
VNS 0.8 ± 0.2 1.1 ± 0.3 1.2 ± 0.1 1.0 ± 0.3 1.3 ± 0.6
Data are mean ± SEM; sham group, n = 10; VNS group, n = 13. Except for CO (p = 0.004) and SSLAD (p\ 0.001), no differences between
groups at baseline
CO cardiac output, dP/dtP = 40 rate of rise in left ventricular (LV) pressure during LV pressure of 40 mmHg, HR heart rate, LVEDP left
ventricular end-diastolic pressure, LVSP left ventricular systolic pressure, MAP mean arterial pressure, PSS post-systolic shortening, SS systolic
shortening, SV stroke volume, VNS vagal nerve stimulation
* p\ 0.05 versus corresponding baseline;  p\ 0.05 versus corresponding 40 min CAO;  p\ 0.05 change by VNS versus corresponding sham
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LNNA had no effect on infarct size, no-reflow area, or
leukocyte influx (Table 3). However, LNNA prevented the
VNS-induced limitation of infarct size (71 ± 6 % in
LNNA ? VNS vs. 65 ± 5 % in LNNA ? sham) and no-
reflow (22 ± 5 % in LNNA ? VNS vs. 13 ± 4 % in
LNNA ? sham), which was paralleled by the prevention
of VNS-induced reduction in leukocyte influx (Table 3).
Role of changes in hemodynamic determinants
of myocardial oxygen demand
Since VNS produced decreases in heart rate and LV sys-
tolic pressure, it could be argued that changes in the
hemodynamic determinants of myocardial oxygen demand
contributed to the cardioprotection by VNS. However, the
observation that LNNA abolished the VNS-induced car-
dioprotection at a time when the hemodynamic effects of
VNS were unmitigated suggests that the cardioprotective
effects of VNS were independent of its hemodynamic
effects. Indeed, regression analysis did not reveal a sig-
nificant correlation between either infarct size (r2 = 0.071)
or no-reflow area (r2 = 0.075), and the double product of
heart rate and systolic arterial pressure (Fig. 6).
Discussion
The present study is the first to investigate the effect of
VNS started just prior to and continued during early
reperfusion on both infarct size and extent of no-reflow in a
large animal model of STEMI, using a clinically transla-
tional protocol. The main findings were that (1) VNS sig-
nificantly limited infarct size and extent of no-reflow; (2)
these effects were accompanied by reductions in regional
infiltration of neutrophils and macrophages; (3) Inhibition
of NO-synthase prevented the cardioprotection by VNS
against necrosis, no-reflow and leukocyte influx.
Table 2 Regional coronary
blood flow and myocardial
metabolism
Baseline Reperfusion
15 min 120 min
CBF (ml/min)
Sham 20 ± 4 34 ± 6* 22 ± 3
VNS 15 ± 1 26 ± 4* 21 ± 2
CBF (ml/beat)
Sham 0.17 ± 0.03 0.30 ± 0.05* 0.21 ± 0.03
VNS 0.14 ± 0.01 0.30 ± 0.06* 0.20 ± 0.02
MVO2 (lmol/min)
Sham 90 ± 20 36 ± 6* 28 ± 4*
VNS 67 ± 7 29 ± 5* 23 ± 3*
MVO2 per beat (lmol/beat)
Sham 0.77 ± 0.13 0.32 ± 0.05* 0.26 ± 0.03*
VNS 0.65 ± 0.13 0.33 ± 0.05* 0.21 ± 0.03*
CVC (ml/min/mmHg)
Sham 0.21 ± 0.05 0.43 ± 0.05* 0.31 ± 0.04
VNS 0.16 ± 0.02 0.32 ± 0.05* 0.29 ± 0.02*
Lactate production (lmol/l/min)
Sham -14 ± 5 10 ± 5* -7 ± 2
VNS -7 ± 1 10 ± 2* -4 ± 2
O2 Extraction (%)
Sham 73 ± 2 19 ± 2* 21 ± 3*
VNS 71 ± 2 19 ± 2* 17 ± 2*
Lactate extraction (%)
Sham 24 ± 4 -13 ± 6* 9 ± 3
VNS 24 ± 5 -15 ± 3* 6 ± 3*
Data are mean ± SEM; sham group, n = 10; VNS group, n = 13
CBF coronary blood flow, CVC coronary vascular conductance (CBF/MAP), MVO2 myocardial oxygen
consumption, O2 extraction myocardial oxygen extraction
* p\ 0.05 versus corresponding baseline;  p\ 0.05 change by VNS versus corresponding sham
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Infarct size
Several studies, though not all [3, 4], indicate that VNS
limits infarct size, when started prior to [8, 21, 54], at [22,
25, 40] or halfway through [39, 48] the onset of myocardial
ischemia (Table 4). The majority of these studies have
been performed in rodents or rabbits, which are sympa-
thetically dominant, and are therefore likely to have a
different sympathico-vagal balance than larger mammalian
species such as pigs and humans. Although it could be
argued that this may enhance the effects of VNS in smaller
animal species with low baseline vagal activity, recent
studies observed that VNS produced similar reductions in
infarct size in swine [39, 40], suggesting that its cardio-
protective effects do not critically depend on basal vagal
activity.
From the studies in Table 4, it is difficult to determine
whether the protective effect of VNS occurred during
ischemia or whether a reduction in lethal reperfusion injury
contributed as well. Two studies in which no reperfusion
was allowed [22, 25] suggest that at least part of the pro-
tective effect is targeted against ischemic cell death. Fur-
thermore, a recent study reported that an intermittent VNS
protocol failed to attenuate infarct size when started at the
very onset of reperfusion [39], questioning whether VNS
can protect against reperfusion injury. In view of the crit-
ical importance of the presence of an intervention during
the golden first minute(s) of reperfusion [42], we hypoth-
esized that continuous VNS started just prior to reperfusion
might be effective against reperfusion injury. Indeed, we
found that VNS, started a few minutes prior to reperfusion,
was able to reduce myocardial infarct size, showing its
cardioprotective potential against lethal reperfusion injury.
The discordance between our findings and the study of
Shinlapawittayatorn et al. [39] may well be due to the
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Fig. 1 Typical examples of effects of VNS on infarct size and no-
reflow. No-reflow is typically located subendocardially
Fig. 2 Effects of VNS on
infarct size and no-reflow of
sham (white square) and VNS
(black square) animals. Data are
mean ± SEM; *p\ 0.05 versus
sham
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difference in VNS algorithm, i.e., intermittent VNS starting
at the very onset of reperfusion [39] versus continuous
VNS starting 5 min prior to reperfusion (Table 4), and may
thus reflect the importance of full VNS during the golden
first minute(s) of reperfusion [42].
The mechanism by which VNS limits infarct size is
presently incompletely understood, but could involve
indirect hemodynamic effects. Thus, the decrease in heart
rate and the rate–pressure product could lower metabolic
demand and modify reactive hyperemia during early
reperfusion, thereby generating favorable (gentle) reper-
fusion conditions [32]. However, most evidence suggests
that VNS-induced cardioprotection is independent of the
reduction in heart rate. Thus, Calvillo et al. [8] showed that
restoring the heart rate to baseline levels by atrial pacing
did not affect cardioprotection by VNS, while several
studies have shown a lack of correlation between the
reduction in heart rate and the reduction in infarct size by
VNS [8, 21, 40]. Those findings are supported by the lack
of a significant correlation between the rate–pressure pro-
duct and infarct size in the present study (Fig. 6). More-
over, coronary reactive hyperemia was not attenuated
during VNS (Supplemental Figure S1), which may have
been due to the opposing effects of the bradycardia-asso-
ciated blunted metabolic stimulus for reactive hyperemia
and the bradycardia-associated increase in diastolic perfu-
sion time. Taken together, these findings suggest that the
VNS-mediated cholinergic activation [8] and muscarinic
receptor stimulation [40] protect against necrosis princi-
pally via a direct myocardial mechanism. Consequently,
we studied the involvement of the reperfusion injury sig-
naling kinase pathway, distal to the muscarinic receptor, by
investigating the role of NO-synthase [9]. NO-synthase
inhibition abolished VNS-mediated cardioprotection, at a
time when the hemodynamic effects of VNS were unper-
turbed, indicating that cardiac NO-synthase activity was
critical for VNS-mediated infarct-size and no-reflow
reductions. These observations are in line with studies from
our laboratory [28, 29] showing an important role for nitric
oxide in cardioprotection against reperfusion injury, likely
by limiting opening of the mitochondrial permeability
transition pore [36, 39, 40]. Future studies are needed to
further investigate the molecular underpinnings of VNS-
mediated cardioprotection.
No-reflow
Reperfusion following a prolonged period of myocardial
ischemia is associated with microvascular obstruction,
termed no-reflow [38]. No-reflow is the result of
endothelial cell damage, deterioration of the glycocalyx,
increased neutrophil plugging, micro-embolization,
microvessel rupture and edema [15, 38]. No-reflow has
been shown to be a strong clinical prognosticator for
long-term outcome [33, 38], which is, at least in part, due
to its close correlation with infarct size [18, 31, 45].
However, recent studies suggest that not only infarct size
[30, 51], but also the extent of no-reflow [17, 33, 38] is an
independent predictor of clinical outcome, which is sup-
ported by experimental studies reporting reductions in no-
reflow by hypothermia [17] or pharmacological interven-
tion [27], independent of a decrease in myocardial infarct
size. These recent insights clearly suggest that novel
strategies to limit no-reflow have significant therapeutic
potential.
The present study is to our knowledge the first to
investigate the effects of VNS on the extent of no-reflow.
VNS markedly reduced no-reflow, which was accompanied
by a reduction in recruitment of macrophages and neu-
trophils to the infarct area. These findings suggest that VNS
modulates the regional immune response and are consistent
with the activation of the cholinergic anti-inflammatory
pathway by VNS [8, 20, 48]. VNS-induced reduction of
no-reflow in the infarct area was prevented by NO-synthase
inhibition in parallel with the abolition of infarct-size
limitation, indicating that NO signaling is critical for the
cardioprotective effects of VNS against both cardiomy-
ocyte necrosis and microvascular obstruction.
Fig. 3 Effects of VNS on early systemic markers for inflammation. Shown are the effects of treatment on TNFa and IL6 levels in circulating
plasma of sham (white square) and VNS (black square) animals. Data are mean ± SEM; *p\ 0.05 versus corresponding baseline
51 Page 8 of 14 Basic Res Cardiol (2015) 110:51
123
Methodological considerations
An intriguing observation in the present study was that the
values for no-reflow of sham animals were considerably
higher in the first (Fig. 2) than in the second (Table 3)
series of experiments. The second series of experiments
was performed approximately 1–2 years after completing
the first series. Plotting all sham–control animals that
underwent 45 min of ischemia and 120 min of reperfusion
in the first series (2011 ? 2012) and in the second series
(2013 ? 2014) demonstrates that the no-reflow area (and
to a lesser extent infarct size) was significantly smaller in
the latter period (Supplemental Figure S2). Although an
explanation is not readily found (same supplier, same
swine breed, same laboratory, same investigators), it
should be noted that the first series was principally per-
formed in the period of February–July, whereas the second
series was performed in the period of August–January,
suggesting that seasonal influences could be involved [24].
Although the present study does not allow identification of
the exact mechanisms underlying these differences, the
observations do emphasize the importance of time-matched
sham–control experiments, as performed in the present
study.
We also observed that while the occurrence of VF was
high in both control ? sham and LNNA-treated swine,
there was a trend toward an increase in intractable VF from
27 % (3 out of 11) in sham animals to 53 % (9 out of 17) in
LNNA-treated animals (p = 0.19). These findings are not
readily explained, but there is evidence that loss of NO
bioavailability increases the susceptibility to VF during
ischemia–reperfusion [2, 6, 23]. Importantly, intractable
VF invariably occurred prior to randomization to sham or
VNS treatment in both control ? sham and LNNA-treated
animals and hence did not affect the study results.
A potential limitation of the present study is that we
studied only the very early effects of VNS on infarct size
and no-reflow in swine with acute myocardial infarction,
with a follow-up limited to 2-h post-reperfusion. This time
point was chosen in view of the demonstrated lack of
development of infarct size and no-reflow over time
between 2 and 5 h of reperfusion [16], so that we do not
expect that infarct size and no-reflow would have evolved
much further beyond the 2-h point. However, the 2-h
reperfusion time was clearly insufficient to allow the VNS-
mediated infarct-size reduction to translate into significant
improvements in regional and global LV function. Future
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studies are required to investigate the long-term effects of
infarct-size and no-reflow reductions by VNS on LV
remodeling and function.
Another methodological consideration is the use of
pentobarbital anesthesia. Pentobarbital is known to possess
vagolytic properties, although this effect appears negligible
in swine, as heart rates under pentobarbital anesthesia ([7];
present study) are not different from the heart rates we
typically observe in awake resting swine [14]. Importantly,
even if vagal tone is reduced, the ability to stimulate the
vagal nerve and induce bradycardia remains principally
intact [5], suggesting that pentobarbital’s vagolytic effects
Fig. 5 Effects of VNS on regional inflammation. Shown are the
effects of treatment on neutrophil and macrophage numbers in
remote, total infarct, infarct–reflow and infarct–no-reflow tissue of
sham (white square) and VNS (black square) animals. Data are
mean ± SEM; *p\ 0.05 versus corresponding remote area;
p\ 0.05 versus corresponding sham; p\ 0.10 versus sham
Fig. 6 Lack of correlation
between the double product of
heart rate and systolic arterial
pressure and infarct size (left
panel) and no-reflow (right
panel) at onset of reperfusion
(45 min CAO)
Table 3 Effects of NO-
synthase inhibition
Control ? sham LNNA ? sham LNNA ? VNS
n = 8 n = 5 n = 6
Area at risk (% LV) 26 ± 2 25 ± 3 27 ± 2
Infarct size (% AR) 50 ± 4 65 ± 5 71 ± 6
No-reflow (% AR) 4 ± 1 8 ± 2 16 ± 4
No-reflow (% IA) 9 ± 2 13 ± 4 22 ± 5
Cell influx in infarct area
Neutrophils (#/mm2) 12 ± 2 7 ± 2 25 ± 6
Macrophages (#/mm2) 58 ± 13 86 ± 35 62 ± 17
Data are mean ± SEM
AR area at risk, IA infarct area, LV left ventricle, n number of animals that survived and completed the
experimental protocol
* p\ 0.05, LNNA ? sham versus control ? sham;  p\ 0.05, LNNA ? sham versus LNNA ? VNS
51 Page 10 of 14 Basic Res Cardiol (2015) 110:51
123
are centrally mediated and do not interfere with efferent
vagal nerve stimulation.
In the present study, a custom-made coil to perform
VNS was used, which may have contributed to a higher
mA than what has been typically used (1–4 mA) in clinical
studies [10, 35, 53] and in a previous study (1–4 mA;
30 Hz, pulse width 0.2 ms) from our laboratory in swine
[7]. The latter was associated with reductions in heart rate
of up to *30 %. Those settings, which are similar to the
settings used in VNS for the treatment of epilepsy and are
well tolerated [37, 46], were similar in frequency and pulse
duration as used in the present study (25 Hz, 0.3 ms), but
the intensity used in the present study (10 mA) was
significantly higher. The fact that we produced slightly
smaller reductions in heart rate at higher VNS intensities
may reflect the custom coil versus the clinical grade coil
that we previously had access to. It is important to note that
this was a proof-of-concept study that did not test a clini-
cally approved device, but investigated the efficacy of VNS
started just prior to reperfusion and continued for only
15 min into reperfusion, in which we were able to
demonstrate cardioprotection, despite a modest 20 %
reduction in heart rate.
Another limitation of the present study is that only a
single VNS protocol was studied and hence it is likely that
other VNS algorithms may afford greater cardioprotection
Table 4 Studies on the cardioprotective effects of vagal nerve stimulation
References Species I/R time Start VNS Duration VNS Infarct size
(% AR)
No-reflow
(% IA)
Pre/onset ischemia
Katare et al. [21] Rat 30 min/2 h 5 min pre-ischemia 35 min Sham 85 ± 3 –
VNS 34 ± 2*
Calvillo et al. [8] Rat 30 min/24 h 5 min pre-ischemia 40 min Sham 53 ± 5 –
VNS 7 ± 1*
Zhao et al. [54] Rat 60 min/2 h 15 min pre-ischemia 75 min Sham 47 ± 4 –
VNS 27 ± 3*
Kong et al. [25] Rat 4 h/0 h Onset ischemia 240 min Sham 52 ± 2 –
VNS 28 ± 2*
Katare et al. [22] Mouse 3 h/0 h Onset ischemia 180 min Sham 56 ± 1 –
VNS 24 ± 2*
Buchholz et al. [3] Rabbit 30 min/3 h 10–15 min pre-ischemia 10 min Sham 52 ± 4 –
VNS 71 ± 4*
Buchholz et al. [4] Rabbit 45 min/4 h 10 min pre-ischemia 10 min Sham 45 ± 2 –
VNS 63 ± 3*
I-VNS 30 ± 3*
Shinlapawittayatorn
et al. [40]
Swine 60 min/2 h Onset ischemia 180 min Sham 46 ± 5 –
VNS 19 ± 4*
I-VNS 5 ± 2*
Early/mid-ischemia
Shinlapawittayatorn
et al. [39]
Swine 60 min/2 h 30 min into ischemia 150 min Sham 46 ± 3 –
I-VNS 19 ± 3*
Wang et al. [48] Rat 30 min/2 h 15 min into ischemia 30 min Sham 72 ± 2 –
VNS 47 ± 3*
Pre/onset reperfusion
Shinlapawittayatorn
et al. [39]
Swine 60 min/2 h Onset reperfusion 120 min Sham 46 ± 3 –
I-VNS 44 ± 3
Uitterdijk et al. Swine 45 min/2 h 5 min pre-reperfusion 20 min Sham 67 ± 2 54 ± 6
VNS 54 ± 5* 32 ± 6*
Data are mean ± SEM
AR area at risk, IA infarct area, I/R infarct/reperfusion time, IS infarct size, VNS vagal nerve stimulation, I-VNS intermittent vagal nerve
stimulation (Buchholz: 10 s on/50 s off; Shinlapawittayatorn: 21 s on/30 s off)
* P\ 0.05 versus corresponding sham. All studies were conducted in vivo except [13]
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[25]. Optimization of the VNS protocol may include
changes in stimulation frequency [1] and extending the
duration of stimulation beyond 15 min of reperfusion.
Clinical implications
The present study demonstrates that VNS starting just prior
to and lasting only 15 min into reperfusion is effective in
reducing infarct size and no-reflow in a large animal model
of reperfused STEMI. VNS thus appears to be an attractive
potential adjuvant therapy to limit reperfusion injury in
patients with STEMI. The current technology includes
implantable stimulators [47]; but with the ongoing devel-
opment of transvenous and transdermal [49, 50] approa-
ches that do not require dissection of the vagal nerve,
investigation of VNS in the clinical setting of STEMI
appears warranted.
Conclusions
The present study in a porcine model of acute myocardial
infarction demonstrated that vagal nerve stimulation
(VNS) started just prior to reperfusion and continued
during early reperfusion-limited infarct size and the extent
of no-reflow. The cardioprotection appeared to occur
independently of the VNS-induced decrease in heart rate
and was not associated with a reduction in systemic
markers of inflammation. However, VNS did result in
reduced neutrophil and macrophage influx into the infarct
area. Finally, NO-synthase activity was required for the
VNS-induced limitation in infarct size and no-reflow.
Taken together, our findings indicate that VNS is a
promising novel adjunctive therapy to limit reperfusion
injury.
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